Breaking News Instant updates and real-time market news.

NVS

Novartis

$85.08

-0.18 (-0.21%)

16:58
10/09/18
10/09
16:58
10/09/18
16:58

Phase 2 study of Novartis's crizanlizumab shows reduced sickle cell pain

Results from a post hoc analysis of the Phase II SUSTAIN study of crizanlizumab, a humanized anti-P-selectin monoclonal antibody being investigated for the treatment of sickle cell disease, have been published in the American Journal of Hematology. The analysis showed that more patients treated with crizanlizumab did not experience a vaso-occlusive crisis, or VOCs, vs those treated with placebo - 35.8% vs 16.9% - specifically patients with a history of 2-10 VOCs in the previous year. The analysis found that treatment with crizanlizumab may prevent VOCs, both in patients who had 2-4 and 5-10 disease-related pain events in the year prior to the study, as well as those with HbSS. Of the subgroups evaluated, a considerable number of patients across multiple subgroups treated with crizanlizumab did not experience a VOC compared with those treated with placebo.

  • 19

    Oct

  • 19

    Oct

  • 07

    Nov

NVS Novartis
$85.08

-0.18 (-0.21%)

09/17/18
FBCO
09/17/18
NO CHANGE
Target $26
FBCO
Neutral
Teva price target raised to $26 from $23 at Credit Suisse
Credit Suisse analyst Vamil Divan reiterated a Neutral rating on Teva Pharmaceutical (TEVA) and raised his price target to $26 after the company said it received FDA approval for Ajovy, a key pipeline drug for migraine prevention and approval of a quarterly dosing for the drug, providing an important point of differentiation relative to competitors from Eli Lilly (LLY) and Amgen (AMGN)/Novartis (NVS). In a research note to investors, Divan says Friday's approval provides Teva with an important potential growth driver as it looks to overcome the challenges it faces with U.S. generics, Copaxone and its large debt load, and expects a "strong" positive reaction in the stock. Divan says he will look to see how Teva commercializes Ajovy in the coming months before becoming more constructive on the stock's longer-term outlook.
09/19/18
PIPR
09/19/18
NO CHANGE
Target $50
PIPR
Overweight
Piper recommends Deciphera into systemic mastocytosis data
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on shares of Deciphera Pharmaceuticals (DCPH) with a $50 price target following a deep dive into the systemic mastocytosis treatment space and the potential for DCC-2618 to play a meaningful role in the disease. The analyst continues to recommend purchase of Deciphera into the systemic mastocytosis data for DCC-2618 early next year. Given what's been presented before between Novartis' (NVS) midostaurin and Blueprint Medicines' (BPMC) avapritinib, Raymond thinks an overall response rate of greater than 50% with a continued clean safety profile should be considered a win for DCC-2618. He models for DCC-2618 systemic mastocytosis revenue of $44M, $151M, and $290M for 2023 through 2025, respectively. The analyst remains a buyer of Deciphera shares into the Q1 of 2019 data.
09/28/18
WELS
09/28/18
NO CHANGE
WELS
Market Perform
Lilly's migraine treatment approval adds to Teva worries, says Wells Fargo
Wells Fargo analyst David Maris noted that Eli Lilly (LLY) received FDA approval of Emgality for the prevention of migraines and announced a U.S. list price of $6,900 annually, which is in line with Teva's (TEVA) Ajovy and Aimovig from Amgen (AMGN) and Novartis (NVS). Lilly's approval adds to Teva investor worries, said Maris, who sees migraines being a competitive market with similar drugs "where the competitors are marketing powerhouses...and Teva is undergoing a lot of organizational change." He maintains a Market Perform rating on Teva shares.
10/08/18
GUGG
10/08/18
INITIATION
GUGG
Neutral
Novartis initiated with a Neutral at Guggenheim
Guggenheim analyst Seamus Fernandez started Novartis with a Neutral rating and CHF 94 price target, stating that its Alcon spin likely will generate value, but he believes additional pipeline catalysts are needed to drive operating leverage.

TODAY'S FREE FLY STORIES

MDT

Medtronic

$93.25

0.65 (0.70%)

11:25
02/22/19
02/22
11:25
02/22/19
11:25
Conference/Events
Medtronic participates in a conference call with JPMorgan »

Healthcare Analyst Marcus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Feb

  • 06

    Mar

  • 18

    May

  • 28

    May

11:15
02/22/19
02/22
11:15
02/22/19
11:15
General news
Fed's Daly said the Fed should aim to hit the 2% inflation target on average »

Fed's Daly said the…

TOT

Total

$56.80

0.74 (1.32%)

11:11
02/22/19
02/22
11:11
02/22/19
11:11
Periodicals
Total cancels sale of Dutch North Sea gas fields, Bloomberg reports »

Total has called off a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 04

    Mar

  • 22

    May

CZR

Caesars

$9.01

-0.41 (-4.35%)

11:10
02/22/19
02/22
11:10
02/22/19
11:10
Options
Post-earnings put roll in Caesars adjusts yesterday's big spread »

Post-earnings put roll in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$294.87

3.69 (1.27%)

, MS

Morgan Stanley

$41.91

-0.05 (-0.12%)

11:07
02/22/19
02/22
11:07
02/22/19
11:07
Periodicals
Tesla CEO looks to Morgan Stanley for five major mortgages, Bloomberg reports »

Tesla (TSLA) CEO Elon…

TSLA

Tesla

$294.87

3.69 (1.27%)

MS

Morgan Stanley

$41.91

-0.05 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Feb

  • 04

    Mar

  • 18

    Mar

  • 19

    Mar

BDRBF

Bombardier

$0.00

(0.00%)

11:05
02/22/19
02/22
11:05
02/22/19
11:05
Hot Stocks
Bombardier to invest $22M in two aerospace research projects in Quebec »

Bombardier announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZG

Zillow

$40.94

5.87 (16.74%)

, Z

Zillow

$41.12

6.09 (17.39%)

11:03
02/22/19
02/22
11:03
02/22/19
11:03
Hot Stocks
Zillow adds to gain as Citron sets $70 target, turns positive after CEO change »

Shares of Zillow Group…

ZG

Zillow

$40.94

5.87 (16.74%)

Z

Zillow

$41.12

6.09 (17.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 11

    Mar

  • 25

    Mar

BECN

Beacon Roofing

$37.50

0.13 (0.35%)

11:02
02/22/19
02/22
11:02
02/22/19
11:02
Hot Stocks
Beacon Roofing announces departure of CEO Paul Isabella later this year »

Beacon Roofing Supply…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

C

Citi

$64.03

-0.28 (-0.44%)

11:00
02/22/19
02/22
11:00
02/22/19
11:00
Options
Active trading in Citigroup short-term puts »

Active trading in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 15

    Apr

  • 28

    May

  • 13

    Jul

ZG

Zillow

$40.54

5.47 (15.60%)

, Z

Zillow

$40.94

5.91 (16.87%)

10:57
02/22/19
02/22
10:57
02/22/19
10:57
Periodicals
Citron says now positive on Zillow, calls returning CEO a 'stud' »

Citron Research tweeted:…

ZG

Zillow

$40.54

5.47 (15.60%)

Z

Zillow

$40.94

5.91 (16.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 11

    Mar

  • 25

    Mar

ZG

Zillow

$40.54

5.47 (15.60%)

, Z

Zillow

$40.94

5.91 (16.87%)

10:57
02/22/19
02/22
10:57
02/22/19
10:57
Periodicals
Breaking Periodicals news story on Zillow, Zillow »

Citron Research turns…

ZG

Zillow

$40.54

5.47 (15.60%)

Z

Zillow

$40.94

5.91 (16.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 11

    Mar

  • 25

    Mar

PFE

Pfizer

$43.02

0.88 (2.09%)

10:55
02/22/19
02/22
10:55
02/22/19
10:55
Periodicals
Pfizer exec to host presidential fundraiser for Gillibrand campaign, CNBC says »

Pfizer's executive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 18

    May

PLNT

Planet Fitness

$59.40

1.14 (1.96%)

10:50
02/22/19
02/22
10:50
02/22/19
10:50
Options
Earnings hedge opened in Planet Fitness »

Earnings hedge opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

FDX

FedEx

$178.46

-3.82 (-2.10%)

, AMZN

Amazon.com

$1,625.63

5.79 (0.36%)

10:44
02/22/19
02/22
10:44
02/22/19
10:44
On The Fly
Stamps.com plummets after announcing discontinuation of USPS partnership »

Shares of Stamps.com…

FDX

FedEx

$178.46

-3.82 (-2.10%)

AMZN

Amazon.com

$1,625.63

5.79 (0.36%)

STMP

Stamps.com

$84.82

-113.26 (-57.18%)

UPS

UPS

$109.32

-2.44 (-2.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 18

    Mar

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

TROX

Tronox

$11.80

0.45 (3.96%)

10:40
02/22/19
02/22
10:40
02/22/19
10:40
Options
Bullish call flow in Tronox ahead of earnings next week »

Bullish call flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

10:40
02/22/19
02/22
10:40
02/22/19
10:40
General news
Fed's Williams: the Phillips Curve is "alive and well" »

Fed's Williams: the…

C

Citi

$64.24

-0.07 (-0.11%)

, INTC

Intel

$52.73

1.33 (2.59%)

10:39
02/22/19
02/22
10:39
02/22/19
10:39
On The Fly
Citi, Intel upgrades, Roku, Nordstrom downgrades among today's top analyst calls »

Check out today's top…

C

Citi

$64.24

-0.07 (-0.11%)

INTC

Intel

$52.73

1.33 (2.59%)

ROKU

Roku

$59.51

8.04 (15.62%)

JWN

Nordstrom

$43.50

-0.97 (-2.18%)

KHC

Kraft Heinz

$34.95

-13.24 (-27.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 03

    Mar

  • 06

    Mar

  • 25

    Mar

  • 26

    Mar

  • 15

    Apr

  • 28

    May

  • 13

    Jul

EA

Electronic Arts

$93.86

-2.97 (-3.07%)

10:37
02/22/19
02/22
10:37
02/22/19
10:37
Periodicals
EA starts massive round of layoffs at Australian studio, Kotaku reports »

Electronic Arts has begun…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

PYX

Pyxus

$24.70

-1.46 (-5.58%)

10:36
02/22/19
02/22
10:36
02/22/19
10:36
Initiation
Pyxus initiated  »

Pyxus initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRX

Xerox

$31.60

0.26 (0.83%)

10:30
02/22/19
02/22
10:30
02/22/19
10:30
Options
Downside hedge opened in Xerox April options »

Downside hedge opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$149.39

32.25 (27.53%)

10:29
02/22/19
02/22
10:29
02/22/19
10:29
Recommendations
Wayfair analyst commentary  »

Wayfair price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 03

    Mar

10:26
02/22/19
02/22
10:26
02/22/19
10:26
General news
Stocks higher as trade talks continue »

Stock futures were higher…

AVEO

Aveo Pharmaceuticals

$0.62

0.0006 (0.10%)

, BMY

Bristol-Myers

$50.47

0.32 (0.64%)

10:25
02/22/19
02/22
10:25
02/22/19
10:25
Conference/Events
Piper Jaffray biotech analysts to hold an analyst/industry conference call »

Biotech Analysts, along…

AVEO

Aveo Pharmaceuticals

$0.62

0.0006 (0.10%)

BMY

Bristol-Myers

$50.47

0.32 (0.64%)

EXEL

Exelixis

$21.28

0.06 (0.28%)

IMMU

Immunomedics

$14.34

0.01 (0.07%)

JNJ

Johnson & Johnson

$135.83

0.43 (0.32%)

MRK

Merck

$80.55

0.73 (0.91%)

NKTR

Nektar

$40.10

-0.16 (-0.40%)

PFE

Pfizer

$42.89

0.75 (1.78%)

SGEN

Seattle Genetics

$69.99

0.74 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 27

    Feb

  • 28

    Feb

  • 06

    Mar

  • 11

    Apr

  • 18

    May

  • 20

    May

  • 17

    Jun

ACER

Acer Therapeutics

$24.25

0.38 (1.59%)

10:25
02/22/19
02/22
10:25
02/22/19
10:25
Conference/Events
William Blair biotech analysts to hold an analyst/industry conference call »

Biotech Analysts, along…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Jun

10:25
02/22/19
02/22
10:25
02/22/19
10:25
Conference/Events
Cowen consumer analysts to hold an analyst/industry conference call »

Consumer Analysts Kernan…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.